PODD

Insulet Corp.
  • Healthcare
  • Medical - Devices
  • $9.14B market cap
Forecast run · Sep 14, 2026Upside rank 590 of 3,136

Model Signal

ForecastQ Daily Probabilities
53.6%
34.4%
19.5%

Analyst Consensus

Recommendation2.50/5 Buy
Last price$131.96
Price target$185.18
Implied move+40.3%
Analysts50

ForecastQ Portfolios

PODD is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ForecastQ

Quantitative stocks signals powered by AI


The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.


© ForecastQ. All rights reserved.